BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results